Portal Hypertension

Categories: Cardiovascular diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Portal Hypertension

MalaCards integrated aliases for Portal Hypertension:

Name: Portal Hypertension 12 73 20 29 15 17 32
Hypertension, Portal 20 44 70
Hypertension Portal 54


External Ids:

Disease Ontology 12 DOID:10762
ICD9CM 34 572.3
MeSH 44 D006975
NCIt 50 C3119
SNOMED-CT 67 155821005
ICD10 32 K76.6
UMLS 70 C0020541

Summaries for Portal Hypertension

GARD : 20 Portal hypertension is abnormally high blood pressure in branches of the portal vein, the large vein that brings blood from the intestine to the liver. Portal hypertension itself does not cause symptoms, but complications from the condition can lead to an enlarged abdomen, abdominal discomfort, confusion, drowsiness and internal bleeding. It may be caused by a variety of conditions, but cirrhosis is the most common cause in Western countries. Treatment is generally directed toward the cause of the condition, although emergency treatment is sometimes needed for serious complications.

MalaCards based summary : Portal Hypertension, also known as hypertension, portal, is related to congenital hepatic fibrosis and varicose veins, and has symptoms including signs and symptoms, digestive An important gene associated with Portal Hypertension is DGUOK (Deoxyguanosine Kinase), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and p70S6K Signaling. The drugs Nadolol and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 73 Portal hypertension is abnormally increased portal venous pressure - blood pressure in the portal vein... more...

Related Diseases for Portal Hypertension

Diseases related to Portal Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 899)
# Related Disease Score Top Affiliating Genes
1 congenital hepatic fibrosis 32.6 PKHD1 AGTR1
2 varicose veins 32.5 VWF VEGFA TNF F2
3 hypersplenism 32.5 THPO GPT F2 ALB
4 budd-chiari syndrome 32.3 JAK2 F3 F2 ALB
5 esophageal varix 32.2 THPO SST PKHD1 GPT F3 F2
6 cholangitis, primary sclerosing 32.0 TNF NR1H4 GPT F2 ALB
7 hepatic encephalopathy 31.9 TNF SST GPT F2 ALB
8 hepatic coma 31.9 GPT F3 F2 ALB
9 schistosomiasis 31.8 TNF GPT F2 ALB
10 hepatoportal sclerosis 31.5 GPT F2 ACE
11 hepatorenal syndrome 31.5 GPT F2 EDN1 ALB ACE
12 thrombosis 31.4 VWF JAK2 F3 F2
13 biliary atresia 31.4 NR1H4 GPT F2 ALB
14 liver disease 31.3 TNF THPO PKHD1 NR1H4 GPT F3
15 liver cirrhosis 31.3 VEGFA UTS2 TNF THPO SST GPT
16 viral hepatitis 31.3 TNF GPT F2 ALB
17 cholestasis 31.3 NR1H4 GPT F2 ALB
18 alcoholic liver cirrhosis 31.2 TNF GPT F2 ALB
19 active peptic ulcer disease 31.1 VWF SST F3 F2 ALB
20 hemorrhoid 31.1 TNF GPT F2 ALB
21 non-alcoholic steatohepatitis 31.1 TNF NR1H4 GPT ALB
22 obstructive jaundice 31.1 TNF GPT F2 EDN1 ALB
23 autoimmune hepatitis 31.0 TNF GPT F2 ALB
24 alcoholic hepatitis 31.0 TNF GPT F2 ALB
25 hepatitis b 30.9 TNF GPT F2 ALB
26 cholangitis 30.9 TNF NR1H4 GPT F3 F2 ALB
27 thrombophilia 30.9 VWF JAK2 F3 F2
28 myelofibrosis 30.9 VEGFA TNF THPO JAK2
29 cholecystitis 30.9 GPT F2 ALB
30 diarrhea 30.9 TNF SST GPT ALB
31 arteriovenous malformation 30.9 VEGFA TNF EDN1 BMPR2
32 cholelithiasis 30.8 SST NR1H4 GPT ALB
33 abdominal tuberculosis 30.8 TNF GPT F2 ALB
34 sclerosing cholangitis 30.8 TNF NR1H4 GPT F2 ALB
35 thrombocytopenia 30.8 VWF TNF THPO JAK2 GPT F3
36 hepatic veno-occlusive disease 30.8 VEGFA THPO F3
37 varicocele 30.8 TNF NOS3 ALB
38 hepatopulmonary syndrome 30.8 VWF VEGFA TNF NOS3 EDNRA EDN1
39 mixed connective tissue disease 30.8 TNF EDNRA BMPR2
40 angiodysplasia 30.7 VWF VEGFA SST F3
41 polycythemia vera 30.7 VWF THPO JAK2 F2
42 alpha-1-antitrypsin deficiency 30.7 TNF GPT F2 ALB
43 neutropenia 30.7 TNF THPO GPT ALB
44 splenic infarction 30.7 JAK2 GPT F3 F2 ALB
45 ileus 30.7 TNF SST F2
46 splenic abscess 30.7 GPT F2 ALB
47 granulomatous hepatitis 30.7 TNF GPT ALB ACE
48 choledocholithiasis 30.7 GPT F2 ALB
49 hereditary hemorrhagic telangiectasia 30.7 VWF VEGFA NOS3 BMPR2
50 antiphospholipid syndrome 30.7 VWF TNF F3 F2

Comorbidity relations with Portal Hypertension via Phenotypic Disease Network (PDN): (show all 22)

Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Chronic Congestive Splenomegaly Chronic Kidney Disease
Deficiency Anemia Esophageal Varix
Heart Disease Hepatic Encephalopathy
Hepatitis Hepatocellular Carcinoma
Hepatorenal Syndrome Hypersplenism
Iron Deficiency Anemia Neutropenia
Portal Vein Thrombosis Primary Biliary Cholangitis
Protein-Energy Malnutrition Urea Cycle Disorder

Graphical network of the top 20 diseases related to Portal Hypertension:

Diseases related to Portal Hypertension

Symptoms & Phenotypes for Portal Hypertension

UMLS symptoms related to Portal Hypertension:

signs and symptoms, digestive

MGI Mouse Phenotypes related to Portal Hypertension:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.51 ACE AGTR1 ALB BMPR2 DGUOK EDN1
2 homeostasis/metabolism MP:0005376 10.46 ACE AGTR1 ALB BMPR2 DGUOK EDN1
3 growth/size/body region MP:0005378 10.41 ACE AGTR1 BMPR2 DGUOK EDN1 EDNRA
4 behavior/neurological MP:0005386 10.4 ACE AGTR1 BMPR2 DGUOK EDNRA F2
5 immune system MP:0005387 10.4 ACE AGTR1 ALB BMPR2 EDNRA F2
6 cellular MP:0005384 10.39 ALB BMPR2 DGUOK EDNRA F2 F3
7 mortality/aging MP:0010768 10.36 ACE AGTR1 ALB BMPR2 DGUOK EDN1
8 hematopoietic system MP:0005397 10.34 ACE AGTR1 BMPR2 EDNRA F3 JAK2
9 digestive/alimentary MP:0005381 10.31 ALB EDN1 EDNRA F2 NOS3 NR1H4
10 endocrine/exocrine gland MP:0005379 10.29 ACE ALB EDN1 EDNRA F2 JAK2
11 embryo MP:0005380 10.21 ACE BMPR2 EDN1 EDNRA F2 F3
12 liver/biliary system MP:0005370 10.16 ACE ALB DGUOK JAK2 NOS3 NR1H4
13 integument MP:0010771 10.13 BMPR2 DGUOK EDNRA F2 F3 JAK2
14 nervous system MP:0003631 10.13 ACE AGTR1 BMPR2 EDN1 EDNRA F2
15 muscle MP:0005369 10.06 ALB BMPR2 EDN1 EDNRA F2 F3
16 normal MP:0002873 10 ALB BMPR2 EDN1 EDNRA F2 F3
17 neoplasm MP:0002006 9.91 ACE ALB F3 JAK2 NR1H4 TNF
18 renal/urinary system MP:0005367 9.85 ACE AGTR1 ALB BMPR2 DGUOK EDN1
19 respiratory system MP:0005388 9.65 BMPR2 EDNRA F2 F3 JAK2 NOS3
20 skeleton MP:0005390 9.36 BMPR2 EDN1 EDNRA F2 GPT JAK2

Drugs & Therapeutics for Portal Hypertension

Drugs for Portal Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Nadolol Approved Phase 4 42200-33-9 39147
Nitric Oxide Approved Phase 4 10102-43-9 145068
Simvastatin Approved Phase 4 79902-63-9 54454
Prazosin Approved Phase 4 19216-56-9 4893
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
Pantoprazole Approved Phase 4 102625-70-7 4679
Esomeprazole Approved, Investigational Phase 4 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
Dalteparin Approved Phase 4 9005-49-6
Warfarin Approved Phase 4 81-81-2 54678486 6691
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
Apixaban Approved Phase 4 503612-47-3 10182969
tannic acid Approved Phase 4 1401-55-4
Dipyridamole Approved Phase 4 58-32-2 3108
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Nadroparin Approved, Investigational Phase 4
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
Lactulose Approved Phase 4 4618-18-2 11333
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
Taurine Approved, Nutraceutical Phase 4 107-35-7 1123
28 Phosphodiesterase 5 Inhibitors Phase 4
29 Vardenafil Dihydrochloride Phase 4
30 Antihypertensive Agents Phase 4
31 Sympatholytics Phase 4
32 isosorbide-5-mononitrate Phase 4
33 diuretics Phase 4
34 Proton Pump Inhibitors Phase 4
35 Mineralocorticoids Phase 4
36 Mineralocorticoid Receptor Antagonists Phase 4
37 Diuretics, Potassium Sparing Phase 4
38 Hypoglycemic Agents Phase 4
39 calcium heparin Phase 4
40 Anti-Arrhythmia Agents Phase 4
41 Pharmaceutical Solutions Phase 4
42 Phosphodiesterase Inhibitors Phase 4
43 Anticoagulants Phase 4
44 Heparin, Low-Molecular-Weight Phase 4
45 Platelet Aggregation Inhibitors Phase 4
46 Serine Proteinase Inhibitors Phase 4
47 Factor Xa Inhibitors Phase 4
48 Antithrombin III Phase 4
protease inhibitors Phase 4
50 Antithrombins Phase 4

Interventional clinical trials:

(show top 50) (show all 224)
# Name Status NCT ID Phase Drugs
1 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
2 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
3 RCT of Carvedilol vs Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
4 Randomized and Controlled Study of Endoscopic Ligation, Nadolol and Isosorbide Mononitrate vs Endoscopic Ligation and Nadolol Alone, or Associated With Isosorbide Mononitrate or Prazosin, Depending of the Hemodinamyc Response Unknown status NCT00563602 Phase 4
5 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
6 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
7 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
8 Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding. Unknown status NCT00414713 Phase 4
9 The Effect of Oral Taurine on Portal Hemodynamics in Patients With Advanced Completed NCT02344719 Phase 4 Taurin 6g per day per oral for 28 days;Placebo 6g per day per oral for 28 days
10 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
11 Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin Completed NCT02994485 Phase 4 Simvastatin
12 Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices Completed NCT00534677 Phase 4 Terlipressin;Octreotide
13 Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension Completed NCT02489045 Phase 4 SHAPE measurement (Sonazoid ultrasoud contrast agent)
14 Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
15 A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Completed NCT03175731 Phase 4 Proton Pump Inhibitors;Placebo
16 Randomized Double Blind Dummy Controlled Trial Of 24 Versus 72 Hours Of Terlipressin As An Adjuvant Therapy In Acute Variceal Bleed Completed NCT00369694 Phase 4 Terlipressin;Terlipressin & then Dummy
17 Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis Completed NCT00570622 Phase 4 Pioglitazone;Placebo
18 Effects of Spironolactone on Fibrosis Progression and Portal Pressure in Patients With Advanced Chronic Liver Disease Completed NCT02907749 Phase 4 Spironolactone and carvedilol;Carvedilol
19 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
20 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension Completed NCT02247414 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
21 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Recruiting NCT01451658 Phase 4 propranolol
22 A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir and Carvedilol in Moderate and Severe Cirrhotic Portal Hypertension Due to Hepatitis B Virus Recruiting NCT02945982 Phase 4 Entecavir+Carvedilol;Entecavir+Carvedilol+ Fuzheng Huayu
23 A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus Recruiting NCT02945956 Phase 4 Entecavir;Entecavir + Fuzheng Huayu
24 Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy Recruiting NCT04645550 Phase 4 Apixaban;Warfarin;Aspirin;Dipyridamole;Low molecular weight heparin
25 Prevention of Hepatic Encephalopathy by Administration of Rifaximin and Lactulose in Patients With Liver Cirrhosis Undergoing TIPS Placement: a Multi-centre Randomized, Double Blind, Placebo Controlled Trial. Recruiting NCT04073290 Phase 4 Rifaximin 550 milligram Oral Tablet [XIFAXAN];Placebo oral tablet;Lactulose 667 milligram/milliliter Oral Solution
26 Early Precise Diagnosis and Intervention of Cirrhotic Portal Hypertension (CPT) Based on a Noninvasive 3D-virtual-model of Hepatic Portal System (3D-vHPS) Active, not recruiting NCT02925975 Phase 4 Carvedilol
27 Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial. Not yet recruiting NCT04353193 Phase 4 Terlipressin;Terlipressin;Octreotide
28 Somatostatin as Inflow Modulator in Adult-to-adult Living Donor Liver Transplantation: a Randomized, Double-blind, Placebo-controlled Trial Not yet recruiting NCT04107428 Phase 4 Somatostatin;Placebo
29 Comparison of Efficacy of 2 Gram Versus 4 Gram Sodium Restriction in the Management of Cirrhotic Ascites Terminated NCT00548366 Phase 4
30 Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
31 Autologous Bone Marrow Stem Cells Infusion Through Hepatic Artery in Open Abdominal Portal Hypertension Surgery for the Treatment of Liver Cirrhosis: a Prospective, Non-randomized, Controlled Study Unknown status NCT01560845 Phase 2, Phase 3
32 Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension (DPH Trial) Unknown status NCT02975323 Phase 3 Carvedilol
33 Effect of Administration "Add on" of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
34 Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
35 Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. Unknown status NCT01798329 Phase 3
36 Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis Unknown status NCT02643212 Phase 3 Rivaroxaban;Placebo
37 Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial Completed NCT01224210 Phase 3 Ambrisentan
38 Noradrenalin vs Terlipressin in Patients With Hepatorenal Syndrome.A Prospective, Randomized Study Completed NCT00370253 Phase 3 Terlipressin;Noradrenalin
39 Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices Completed NCT00493480 Phase 3 carvedilol;propranolol
40 Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy Completed NCT02134626 Phase 3 Simvastatin;Placebo pill
41 Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial Completed NCT01000779 Phase 3 Propranolol
42 The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension Completed NCT00331188 Phase 3 Sanvar® (vapreotide)
43 Randomized Trial, Masked, and Placebo Controlled to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension Completed NCT01456286 Phase 2, Phase 3 sapropterin
44 Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis Completed NCT00006398 Phase 3 Timolol Maleate;Placebo
45 A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding Completed NCT01095185 Phase 3 Simvastatin;Placebo
46 The Effectiveness of L-ornithine-L-aspartate on Plasma Ammonia in Cirrhotic Patients After TIPS Procedure: a Prospective, Randomized, Controlled, Open-label Clinical Trial Completed NCT01440829 Phase 2, Phase 3 L-ornithine-L-aspartate
47 Control of Acute Variceal Bleeding Using the Multi-shooter Band Ligator Compared to Injection Sclerotherapy. Completed NCT01131962 Phase 3
48 A Randomized Control Clinical Trial Between Precise Hepatectomy and Combined Interventional Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension Recruiting NCT01642446 Phase 3
49 A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis Recruiting NCT04365868 Phase 2, Phase 3 belapectin;Placebo
50 Hepatic Resection Versus Radiofrequency Ablation for Patients With Hepatocellular Carcinoma and Portal Hypertension Recruiting NCT02192671 Phase 3

Search NIH Clinical Center for Portal Hypertension

Cochrane evidence based reviews: hypertension, portal

Genetic Tests for Portal Hypertension

Genetic tests related to Portal Hypertension:

# Genetic test Affiliating Genes
1 Portal Hypertension 29

Anatomical Context for Portal Hypertension

MalaCards organs/tissues related to Portal Hypertension:

Liver, Spleen, Kidney, Endothelial, Pancreas, Bone, Heart

Publications for Portal Hypertension

Articles related to Portal Hypertension:

(show top 50) (show all 18574)
# Title Authors PMID Year
Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. 54 61
20428787 2010
Long-acting somatostatin analogue therapy in obscure-overt gastrointestinal bleeding in noncirrhotic portal hypertension: a case report and literature review. 61 54
19491695 2010
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. 54 61
19582578 2010
Long-term outcome and management of hepatopulmonary syndrome in children. 54 61
19686444 2010
Portal hypertension in primary biliary cirrhosis (PBC): A reversible condition? Yes, but not in all UDCA treated patients. 61 54
19796042 2009
Urotensin II modulates hepatic fibrosis and portal hemodynamic alterations in rats. 61 54
19797237 2009
Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. 61 54
19446911 2009
Reticulated platelets and thrombopoietin in schistosomiasis patients. 54 61
19143871 2009
Pathobiology of secondary immune thrombocytopenia. 54 61
19245930 2009
Innate immune dysfunction in acute and chronic liver disease. 61 54
20047110 2009
Ascites: aetiology, mortality and the prevalence of spontaneous bacterial peritonitis. 61 54
19440927 2009
Anicteric cholangiopathy in schistosomiasis patients. 61 54
18598665 2008
Cannabinoid receptors as therapeutic targets in the management of liver diseases. 61 54
19259549 2008
Increased circulating urotensin II in cirrhosis: potential implications in liver disease. 54 61
17913301 2008
Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. 61 54
18318439 2008
[The role of urotensin II in human pathophysiology]. 61 54
19323069 2008
[Analysis of risk factors for selective devascularization in patients with portal hypertension]. 61 54
18509995 2008
New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. 61 54
17608670 2007
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. 61 54
17918268 2007
Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. 61 54
18023093 2007
Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. 54 61
17919235 2007
Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. 54 61
17958515 2007
Other immune thrombocytopenias. 61 54
18096469 2007
Right liver lobe/albumin ratio: contribution to non-invasive assessment of portal hypertension. 54 61
17879402 2007
The puzzle of endothelial nitric oxide synthase dysfunction in portal hypertension: The missing piece? 54 61
17879360 2007
Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. 54 61
17417733 2007
Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. 61 54
17608860 2007
The role of thrombopoietin and spleen volume in thrombocytopenia of patients with noncirrhotic and cirrhotic portal hypertension. 54 61
17602356 2007
Insulin resistance in liver cirrhosis is not associated with circulating retinol-binding protein 4. 54 61
17337499 2007
Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. 61 54
17174610 2007
A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. 54 61
17416468 2007
Q-T interval (QT(C)) in patients with cirrhosis: relation to vasoactive peptides and heart rate. 61 54
17852825 2007
[Prevention and treatment of esophageal variceal bleeding]. 61 54
17378164 2006
New insights into the coagulopathy of liver disease and liver transplantation. 54 61
17203512 2006
Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. 61 54
16919014 2006
Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial. 61 54
16434427 2006
Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. 61 54
16771945 2006
Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. 54 61
16573786 2006
GRK2 makes trouble: a no-NO in portal hypertension. 54 61
16530538 2006
Myosin phosphatase isoform switching in vascular smooth muscle development. 54 61
16356512 2006
[Hepatorenal syndrome]. 61 54
17203812 2006
Effects of somatostatin, terlipressin and somatostatin plus terlipressin on portal and systemic hemodynamics and renal sodium excretion in patients with cirrhosis. 61 54
15955217 2005
Expression of angiotensin II type 1 receptor in human cirrhotic livers: Its relation to fibrosis and portal hypertension. 61 54
15905119 2005
The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. 61 54
15929762 2005
[A study of the association of iNOS and eNOS gene polymorphism with portal hypertension in liver cirrhosis]. 61 54
15918973 2005
Hepatorenal syndrome. 61 54
15381144 2005
Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension. 54 61
15647641 2005
Hepatorenal syndrome. 54 61
15920325 2005
Urotensin II: its function in health and its role in disease. 61 54
15883758 2005
[Factors influencing clinical course of viral hepatitis]. 61 54
16381233 2005

Variations for Portal Hypertension

Expression for Portal Hypertension

Search GEO for disease gene expression data for Portal Hypertension.

Pathways for Portal Hypertension

Pathways related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
12.62 NOS3 JAK2 F2 EDN1 AGTR1
Show member pathways
Show member pathways
12.36 TNF NOS3 JAK2 F2 AGTR1
Show member pathways
11.63 NOS3 AGTR1 ACE
10 11.42 VEGFA NOS3 EDN1
11 11.38 JAK2 EDNRA EDN1
13 11.17 VEGFA TNF NOS3 JAK2 F3 EDN1
14 11.11 NOS3 EDNRA EDN1
Show member pathways

GO Terms for Portal Hypertension

Cellular components related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VWF VEGFA UTS2 TNF THPO SST
2 caveola GO:0005901 9.5 NOS3 JAK2 BMPR2
3 extracellular space GO:0005615 9.44 VWF VEGFA UTS2 TNF THPO SST
4 platelet alpha granule lumen GO:0031093 9.43 VWF VEGFA ALB
5 Weibel-Palade body GO:0033093 9.16 VWF EDN1

Biological processes related to Portal Hypertension according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.16 UTS2 SST JAK2 F2 EDNRA EDN1
2 positive regulation of cell migration GO:0030335 9.95 VEGFA JAK2 F3 EDN1
3 positive regulation of protein phosphorylation GO:0001934 9.9 VEGFA TNF THPO F2
4 blood coagulation GO:0007596 9.89 VWF JAK2 F3 F2
5 positive regulation of cell proliferation GO:0008284 9.88 VEGFA THPO PKHD1 JAK2 F2 EDN1
6 positive regulation of protein kinase B signaling GO:0051897 9.86 VEGFA TNF THPO F3
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 VEGFA TNF JAK2
8 positive regulation of endothelial cell proliferation GO:0001938 9.81 VEGFA F3 BMPR2
9 positive regulation of endothelial cell migration GO:0010595 9.8 VEGFA EDN1 BMPR2
10 positive regulation of cytosolic calcium ion concentration GO:0007204 9.78 JAK2 EDNRA EDN1 AGTR1
11 positive regulation of MAP kinase activity GO:0043406 9.74 VEGFA TNF EDN1
12 kidney development GO:0001822 9.73 VEGFA PKHD1 AGTR1 ACE
13 hemostasis GO:0007599 9.7 VWF F3 F2
14 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.69 TNF JAK2 EDN1
15 positive regulation of positive chemotaxis GO:0050927 9.65 VEGFA F3
16 artery smooth muscle contraction GO:0014824 9.64 EDNRA EDN1
17 negative regulation of platelet activation GO:0010544 9.63 NOS3 F2
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.63 TNF JAK2 EDN1
19 endothelial cell apoptotic process GO:0072577 9.61 TNF BMPR2
20 regulation of glucose transmembrane transport GO:0010827 9.61 EDNRA EDN1
21 endothelin receptor signaling pathway GO:0086100 9.58 EDNRA EDN1
22 positive regulation of axon extension involved in axon guidance GO:0048842 9.58 VEGFA BMPR2
23 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.55 NOS3 EDN1
24 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.54 AGTR1 ACE
25 blood vessel remodeling GO:0001974 9.54 NOS3 BMPR2 ACE
26 branching involved in blood vessel morphogenesis GO:0001569 9.5 VEGFA EDNRA EDN1
27 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.49 VEGFA ACE
28 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.46 VEGFA TNF JAK2 F2
29 regulation of vasoconstriction GO:0019229 9.43 EDN1 AGTR1 ACE
30 regulation of blood vessel diameter GO:0097746 9.26 UTS2 NOS3 AGTR1 ACE
31 regulation of blood pressure GO:0008217 9.02 UTS2 NOS3 EDNRA EDN1 ACE

Molecular functions related to Portal Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 VEGFA TNF THPO EDN1
2 signaling receptor binding GO:0005102 9.55 UTS2 THPO JAK2 F2 EDN1
3 hormone activity GO:0005179 9.26 UTS2 THPO SST EDN1
4 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Portal Hypertension

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....